Clinical Trial Update: Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the initial administration of intravenous vortioxetine 17 mg with 10 mg/day oral vortioxetine for major depressive disorder has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED